Statera BioPharma Inc (STAB)

[Sesh]

Statera is being stolen from the original Russian investors and giving to the Saudis.

[Sesh]

You’re not understanding what’s happening here.

This company is being stolen…the same way the system is stealing Russian yachts.

It’s being stolen by bankers, that’s why it’s lost value for shareholders. This company has done absolutely nothing wrong, ever.

[Sesh]

The market value for a phase 3 molecule is 1.1 billion usd and costs 154 million to get to market.
Statera has followed the path the market has created for molecule development to the T.
So all of the complaints about “financials” are from people who have a problem with how the drug industry is set up, not Statera.

[ssc]

Believe what you want, but these guys look as shady as it gets. Completely destroyed all value for any cbli shareholders who were unfortunate enough to hold on after the merger.

[Sesh]

The financials for Statera are exactly like every other Biotech company that has a phase III ready molecule.
That is the way the market is set up.

They were right at the phase III stage, the only reason they didn’t have a massive payday is because they had a lab in Russia when Biden put all the sanctions on Russian assets.

[ssc]

Need to look at financials for stab and reverse stock splits. After merging with cbli, statera quickly burned thru all its cash. Share price went from $9 to 15 cents.

1/2 million in cash

Burns $millions/quarter

$14 million a/p and accrued expenses

No products approved for sale

1:20 reverse split in 2015

1:20 reverse split about to happen

Shell game of private placements, promissory notes, Bahamas connection, etc.

No surprise this stock is worth only pennies/share.

[Sesh]

So Pfizer and Moderna both funded the bioweapon research in China through various means.
They both made incredible profits by doing so.
Do you think they’re just gonna stop now?
Do you think the CCP is just gonna stop it’s bioweapon program and doesn’t have another one already prepared to launch if they want to?

[Sesh]

And now because of whatever this is here. When the market needs what Statera has, because they didn’t understand what was happening now, will have to depend on a Saudi investment company to give it to them.
Pfizer and Moderna failed to stop the bioweapon, failed.
So what happens when the next one comes?

[Sesh]

Pfizer’s biggest operation is in China. So this market believes that the company that gives a lot of money directly to the CCP bioweapons program aka Pfizer should have all the money and resources available to help them create their next attack.
And a company like Statera that develops the technology to combat bioweapons is worthless.
Well guess what, they’ve got it wrong. But who cares right let’s just keep funding the same system that has failed over and over and over instead of learning about what’s happening and fixing it.

[Sesh]

So it’s now coming out that SARSCOV2 is part of the CCP Bioweapon program. Estimated they moved that virus capability 150,000 years into the future.
The market is so saturated with people who don’t understand what that means they’re just letting stocks like Statera get bought out by foreign investors.
This is the aftermath of a market that is so heavily dependent on the fed that it has lost the ability to think for itself.

[Sesh]

See what I mean, it’s just going through the motions at this point when it’s being shorted. Nobody is surprised, nobody cares except a couple shorts because they’re psycho. Beating a dead horse I think it’s called.

[Sesh]

Do an Internet search “toll like receptors and mRNA”

You’ll see what I’m talking about.

[Sesh]

So crazy to watch the market destroy this stock to put new majority owners in place.

[Sesh]

The definition of a vaccine was changed because of the new mRNA technology.

That’s what Statera has, they have the same technology that Moderna and Pfizer are using and being evaluated for so many billions.
But they don’t have vaccines like PFE and MRNA sold, they have the area/disease specific treatments that mRNA technology was invented for in the first place.

[Sesh]

This company is being stolen from the original owners/investors right now at dirt cheap prices, like the kind of prices you can only get when you’re successfully stealing a company.

[Sesh]

Gene editing, specific organs being injected with treatments to treat and prevent diseases, combining human tissue with robotics…a whole new generation of medicine is emerging rapidly.

Their TLR platform is very valuable in all of it…

[Sesh]

Have you seen the new CRISPR commercials for the babies in pods?

Have you seen Moderna’s new cancer vaccines?

Have you seen the infertility problems globally?

Statera’s platform is right at the very top of the new generation of med treatments emerging.

Whoever owns majority here will control a big portion of the future of medicine. That’s why it’s caught up in this huge fight that involves a whole bunch of players and very elaborate plans to steal the company from the original investors.

[Sesh]

If there was no Russia/Ukraine conflict
the shorts would have had absolutely nothing here except for general market conditions.

The company has rebuilt itself in a way that separates it from the only functioning driver behind this insane low price.

The shorts have nothing, nothing except for a last trace of illegitimate vapor from the Big Short that already happened here.

[INFINITI]

Idiot sellers

[INFINITI]

Dip then rip again

[INFINITI]

Load up 500% doable here

[INFINITI]

Let’s run this bad boy cmon $$$$

[INFINITI]

Whatever it is I’m in $$$$$

[oldgrowth28]

https://reporter.am/2022/07/21/statera-biopharma-inc-nasdaqstab-short-interest-update.html
$STAB

[goforthebet]

and yet a new scam in the making with old staff... lol

https://opencorporates.com/companies/us_fl/F22000002945

[ssc]

Difficult to believe people were sucked into buying this turd above 26 cents for the last 2 weeks. It's not like the dire financial position and terrible management performance are secrets.

[goforthebet]

why I am not surprised - lol

This company is a complete failture

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 18, 2022 indicating that, because the Company was delinquent in filing its quarterly report on Form 10-Q on May 15, 2022 for the first quarter ended March 31, 2022, the Company had not complied with Nasdaq Listing Rule 5250(c)(1) for continued listing.

Statera is searching to identify a new independent registered public accounting firm. The Company will disclose the engagement of the new firm in accordance with SEC rules and regulations once the process has been completed. The Company recently restructured to reduce cash burn and conserve resources. The Company is also working to complete the previously announced transactions with Coeptis Therapeutics, Inc. and Immune Therapeutics, Inc. to out-license certain assets. In addition, the Company has the potential to reinvirogate its pipeline with certain assets from Lay Sciences, Inc. as previously announced.

On April 19, 2022, the Company received notification from Nasdaq that it had failed to comply with Nasdaq Listing Rule 5250(c)(1) because it was delinquent in filing its Annual Report on Form 10-K for the period ending December 31, 2021. In a subsequent letter dated May 18, 2022 the Company received further notification from Nasdaq that it had failed to comply with Nasdaq Listing Rule 5250(c)(1) because it was delinquent in filing its Quarterly Report on Form 10-Q for the three-month period ending March 31, 2022.

In accordance with Nasdaq’s letters dated April 19, 2022 and May 18, 2022, the Company has until June 20, 2022 to submit a plan to regain compliance with respect to the delinquencies described in this announcement. Any Nasdaq exception to allow the Company to regain compliance, if granted, will be limited to a maximum of 180 calendar days from the due date of the initial delinquent filing of the Company’s 2021 Form 10-K, or October 17, 2022. The Company intends to submit a timely plan.

[ssc]

Wow, exciting stuff. How can stab still be at 25 cents? Oh yeah, no cash, no revenues, in violation of NASDAQ listing requirements and horrible management team.

[bobbleheadtwin]

The option agreement with the University of Pittsburgh marks the third material event for Coeptis this quarter and follows the recently announced definitive merger agreement with Bull Horn Holdings Corp. ["Bull Horn"] (Nasdaq: BHSE ), a special purpose acquisition company (SPAC) that is anticipated to close in the third quarter of 2022. Additionally, in April, Coeptis entered into a strategic agreement with Statera Biopharma, Inc. that gives Coeptis the right to acquire, subject to satisfaction of certain conditions, Statera's toll-like receptor 5 (TLR5) agonist platform, including entolimod, a clinical-stage product currently being developed as a treatment for acute radiation syndrome.

[maxmax47]

Well, you were right and I was wrong. I really thought this stock was going to jump up. I bailed with a nice loss today. On to the next one......

[maxmax47]

Huh? 200%? Try 500% plus. LOL.

I said I BOUGHT back in at .28 level. Oh, ya, I also bought more at the .25 level today as well. Just saying.....

Not trying to get into some debate with you but literally the 52 week low is .20 and the 52 week high is over $7. Those numbers were before their recent deals which will increase revenue dramatically. Have you taken a look at the institutional investors in this stock? Might want to do that and re evaluate your short position on this....IMO

Just my opinion but I think there will a dramatic move up very soon in this stock even if one just looks at the charts and does not pay attention to their news.
All the best.

[ssc]

So downside risk minimal and expecting a 200% or more increase from the 33 cent level but not buying. Kind of strange.

[maxmax47]

Sure... the dow got absolutely slaughtered and tanked over 1k points but this little stock managed to stay green all day through the blood bath.....

[maxmax47]

Nope, I bought back into the stock for my round 2 during that .28 dip the other day.
Nothing I have read leads me to think it would be wise to buy puts for instance on this stock. The upside potential is too huge here and the downside risk is minimal in my view.

[ssc]

Got an update on stab movement today?

[mining101]

Agree

[ssc]

So you're a buyer here at .37?

[maxmax47]

They deleted my last reply. However, the stock is up 14% today at this moment and I believe it will go over a dollar in the very near future.

[ssc]

Do you have any idea about:

how much 5% of imun stock is worth?

how imun will pay $2 million in cash when they have a small fraction of that on their balance sheet?

how many years (decades) it will take for imun to actually get to the point of producing revenues? They have zero revenues now.

how stab will stay in business with no cash and no revenues as they wait for imun to get approval and actually market anything that is part of this deal?

Well, the good news for anyone like you is that they can buy all the shares of stab they want at these bargain prices lol. It has been a bargain all the way down from $7.

[maxmax47]

Perhaps. However, it is a 400 million dollar plate......so should the stock be worth more than .28 soon? My bet is yes, a whole lot more. "Under the expected terms of the deal, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics. Statera will also receive payments for, among other things, achievement of revenue-based milestones, new indications and royalties, in exchange for its rights to any product containing low-dose naltrexone as an active ingredient, the companies said.

In aggregate, the deal could generate over $400 million in non-dilutive payments to Statera, the company said."

Just saying....

[ssc]

There is a difference between being on a plate and being a possibility with numerous contingencies and financing requirements with a company with no revenues. There is a reason, actually a few of them, for stab going from $7 to 30 cents. Read and understand the financials. Also continued Nasdaq listing in jeopardy. Just saying.....

[dfloy]

I see you. Market makers trying to use the bid to stop the price from moving up.

[maxmax47]

Absolutely! But it did allow me to buy more in the .28 range just now.... lol! Wait until this thing runs again... it should really soon IMO....look at the year chart, for goodness sakes it was over $6 last July with no 400 million dollar deal on its plate. Just saying......

[dfloy]

Low volume price manipulation is rampant.

[INFINITI]

I agree

[ssc]

Seriously? Projected revenue? From a term sheet about a deal that isn't close to being done, with a company that has no revenues and little cash, for products that have yet to be approved, and contingent on imun fund raising? Lucky to stay above 5 cents.

[maxmax47]

yup! 400 mil in projected revenue... and it is at .33? This stock should be over $5 very soon.imo

[mining101]

Squeeeeeze

[mining101]

Lows almost tested - about to squeeze

[iwanttomakemoney]

Absolutely!!! .50 coming